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OsteoporosisMicroRNA (miR)-150 has been shown to control B and T cell differentiation in the bonemarrow. The regulation of
B and T cells is directly or systematically associatedwith bone remodeling cells such as osteoclasts; however, the
functional role of miR-150 in bone homeostasis has not been well studied. Here, we observed down-regulation
of miR-150 during in vitro osteoclast differentiation and, furthermore, that miR-150 knockout mice exhibit
decreased bonemass and an increased number of osteoclasts. miR-150 deﬁciency did not affect osteoclast differ-
entiation, but miR150 knockout mice had signiﬁcantly lower osteoprotegrin (OPG) serum levels, suggesting that
the reduction of serum OPG level in miR-150 knockout mice might induce B cell expansion and subsequently
increase serum levels of immunoglobulins for activating osteoclast differentiation.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
MicroRNAs (miRNAs) are evolutionarily conserved small non-
coding RNAs that post-transcriptionally repress target genes by binding
their 3′ untranslated regions. Inmaintaining bone homeostasis, miRNAs
regulate the differentiation of bone precursor cells into osteoclasts and
function of mature osteoclasts in a cell-restricted and/or paracrine/
endocrine manner (Gamez et al., 2014; van der Eerden, 2014). In a pre-
vious study, 9miRNAswere clinically identiﬁed as being up-regulated in
the serum of osteoporosis patients, and 6miRNAs exhibited signiﬁcantlyarrow-derived macrophages;
-resistant acid phosphatase;
, receptor activator of nuclear
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. This is an open access article underhigher expression in the bone tissue of osteoporotic patients (Seeliger
et al., 2014).
The aberrant in vivo biogenesis of miRNAs consequently leads to
an imbalance of bone remodeling due to the over-activation and/or
increased number of bone resorptive osteoclasts, resulting in low bone
density, a state by which bone-related disorders such as osteoporosis,
rheumatoid arthritis and cancer are characterized (van Wijnen et al.,
2013; Papaioannou et al., 2014). Basically, hematopoietic stem cells
(monocytes and bone marrow-derived macrophages, BMMs) differen-
tiate into multinucleated osteoclast cells (MNCs) accompanied by the
induction of tartrate-resistant acid phosphatase (TRAP), a biomarker
of osteoclast differentiation. The formation of TRAP-positive MNCs
(TRAP+-MNCs) is directly induced by two essential cytokines: macro-
phage colony-stimulating factor (M-CSF) and receptor activator of
nuclear factor-κB ligand (RANKL) (Boyle et al., 2003). In particular, the
binding of RANKL to its receptor RANK triggers the activation of signal-
ing cascades for osteoclast differentiation, but the action of RANKL is
modulated by a decoy receptor, osteoprotegrin (OPG) (Simonet et al.,
1997).
Osteoclast differentiation is also complicatedly regulated by immune
cells and their activation and/or the cytokines they produce, such that
osteoclast activity can be deregulated by autoimmunity or high inﬂam-
mation (Long & Humphrey, 2012). Because the immune and skeletalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Primer sequences used in this study.
Target gene Forward (5′-3′) Reverse (5′-3′)
c-Fos CTGGTGCAGCCCACTCTGGTC CTTTCAGCAGATTGGCAATCTC
NFATc1 GGGTCAGTGTGACCGAAGAT GGAAGTCAGAAGTGGGTGGA
TRAP ACTTCCCCAGCCCTTACTAC TCAGCACATAGCCCACACCG
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA
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and crosstalk (Takayanagi, 2007), an understanding of the osteo-
immunological pathogenesis of bone-related diseases could be helpful
for identifying novel therapeutic targets in miRNAs.
The importance of miR-150 in the maturation of immune cells has
been reported in several studies (Xiao et al., 2007; Zhou et al., 2007;
Bezman et al., 2011; Zheng et al., 2012), but its relevance to bone
homeostasis has not been studied. In preliminary studies, we found
that miR-150 expression was down-regulated during in vitro osteoclast
differentiation. Therefore, in this study,we investigated the relevance of
miR-150 to bone metabolism by determining whether miR-150 would
affect morphological changes to bone in miR-150 knockout mice.
2. Materials and methods
2.1. Mice
Mice homozygous for the miR-150-knockout allele (miR-150−/−)
and wild-type C57/B6J were purchased from JAX Mice (Bar Harbor,
ME), and identiﬁed by genotyping PCR according to the published pro-
tocol (http://www.jax.org). Animal care was performed in compliance
with the Guide for the Care and Use of Laboratory Animals, from the
Institute for Laboratory Animal Research at the Korea Research Institute
of Bioscience and Biotechnology.
2.2. Preparation of mouse osteoclast precursor cells
The isolation of mouse BMMs and their differentiation into osteo-
clasts were carried out according to the guidelines of the Institutional
Animal Care and Use Committee of the Korea Research Institute of
Chemical Technology. BMMs were isolated as previously described
(Choi et al., 2012). In detail, after cervical dislocation, bone marrow
cells (BMCs) were obtained from 5-week-old male ICR mice (Damool
Science, Daejeon, Korea) by ﬂushing femurs and tibias with α-MEM
supplemented with antibiotics (100 units/ml penicillin and 100 μg/ml
streptomycin; Invitrogen Life Technologies, CA). BMCs were cultured
on a culture dish in α-MEM supplemented with 10% fetal bovine
serum (FBS; Invitrogen Life Technologies, CA) with 10 ng/ml of mouse
recombinant M-CSF (R&D Systems, MN) for 1 day. Then, after non-
adherent BMCs were replated on a Petri dish and cultured for 3 days
in the presence of M-CSF (30 ng/ml), adherent BMMs were used for
osteoclast differentiation.
2.3. Osteoclast differentiation
Isolated BMMs (1 × 104 cells/well in a 96-well plate or 3 ×
105 cells/well in a 6-well plate) were seeded and cultured in the pres-
ence of the indicated concentration of mouse recombinant RANKL
(R&D Systems, MN) and M-CSF (30 ng/ml) for 4 days to differentiate
into mature MNCs.
2.4. TRAP staining and activity assay
Mature osteoclasts were visualized by TRAP staining. Brieﬂy, MNCs
were ﬁxed with 3.7% formalin for 10 min, permeabilized with 0.1%
Triton X-100 for 10 min, and stained with TRAP solution (Sigma-
Aldrich, MO). TRAP+-MNCs (≥3 nuclei) were counted. To measure
TRAP activity, MNCs were ﬁxed in 3.7% formalin for 5 min, perme-
abilized with 0.1% Triton X-100 for 10 min, and treated with a TRAP
buffer (100mMsodium citrate pH5.0, 50mMsodium tartrate) contain-
ing 3 mM p-nitrophenyl phosphate (Sigma-Aldrich, MO) at 37 °C for
5 min. Reaction mixtures in the wells were transferred to new plates
containing an equal volume of 0.1 N NaOH and the optical density was
determined at 405 nm.2.5. RNA isolation and real-time polymerase chain reaction (PCR)
According to the manufacturer's protocols, total RNA was isolated
with TRIzol reagent (Invitrogen Life Technologies, CA), and reverse
transcription was performed with 1 μg of RNA using oligo(dT) primers,
dNTP, RNase inhibitor and SuperScript II reverse transcriptase
(Invitrogen Life Technologies, CA). For evaluating mRNA expression
levels, SYBR green-based PCR was performed with the Stratagene
Mx3000 Real-Time PCR system and Brilliant SYBR Green Master Mix
(Stratagene, CA) as described previously (100). Table 1 lists the primers
used in this study. GAPDHwas used as an internal control. The miR-150
primers were purchased from Exiqon (MA). For evaluating the expres-
sion levels of miR-150, miR SYBR Green Master Mix (Exiqon, MA) was
used according to the manufacturer's protocol. U6 primers were pur-
chased from Exiqon, and used as an internal control for miRNA.
2.6. Western blot analysis
Cells were lysed in ice-cold lysis buffer (50 mM Tris–HCl, 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM sodium ﬂuoride, 1 mM
sodium vanadate, and 1% deoxycholate) supplemented with 1 mM
phenylmethylsulfonyl ﬂuoride (PMSF; BIO BASIC Inc., CA). The lysates
were centrifuged at 12,000 ×g for 10 min. The protein concentration
in the supernatant was determined using the DC protein assay kit
(Bio-Rad, CA) according to the manufacturer's protocol. Proteins
(20 μg) were boiled in sodium dodecyl sulfate (SDS) sample buffer for
5 min, separated in an 8% SDS-polyacrylamide electrophoresis gel and
transferred onto a polyvinylidene diﬂuoride membrane (Amersham
Biosciences, NJ). Themembranewas preincubated at room temperature
with 5% skim milk in TBST (0.1% Tween 20 in Tris-buffered saline) for
1 h, probed with a primary antibody against NFATc1 or actin (Santa
Cruz Biotechnology, TX), and incubated overnight at 4 °C. The mem-
branewaswashedwith TBST three times for 30min and then incubated
at room temperature with a horseradish peroxidase-conjugated sec-
ondary antibody (Santa Cruz Biotechnology, TX) for 2 h. After washing
with TBST, the immunoblotting signals were detected using the Super-
Signal West Pico Chemiluminescent Substrate (Pierce Chemical Co., IL)
with an LAS-3000 luminescent image analyzer (Fuji Photo Film Co.,
Japan).
2.7. Micro-computed tomography (μCT) and histological analysis
Bone histomorphometric analyses were performed in Genoss
Co. (Korea) with a μCT scanner (SkyScan1173, Bruker Corporation,
Germany), and the images were obtained using DataViewer (SKYSCAN).
All histomorphometric parameters were described in accordance with
standard criteria (Dempster et al., 2013; Bouxsein et al., 2010). Femurs
were ﬁxed in 4% paraformaldehyde in phosphate buffered saline (PBS)
overnight, decalciﬁed in 12% EDTA, hydrated, parafﬁn-embedded, sec-
tioned, and stained with hematoxylin and eosin (H&E) and the TRAP
solution kit (Sigma-Aldrich, MO).
2.8. Enzyme-linked immunosorbent assay (ELISA)
Blood serums were collected from the infraorbital venous plexus of
mice (13-week-old, male, n = 7) using a heparinized capillary tube
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by an ELISA assay. ELISA kits for RANKL or OPG quantiﬁcation were ob-
tained from Abcam (MA). ELISA kits for tumor necrosis factor (TNF)-α,
and interferon (IFN)-γ quantiﬁcation were obtained from R&D Systems
(MN). Assayswere performed according to themanufacturers' protocol.Fig. 1.miR-150 is down-regulated during osteoclast differentiation and its knockout mice exh
levels of miR-150 during RANKL-induced osteoclast differentiation were evaluated by real-ti
0 day. (B) Bodyweights of thewild-type andmiR-150 knockout mice (KO; 13-week-oldmale, n
isolated from the wild-type and miR-150 knockout mice were generated by μCT. (D) BMD, B
software. *** P b 0.001, vs. thewild type. (E) Histological analysiswas performed by H&E and TR
*P b 0.05, vs. the wild type.2.9. Statistical analysis
All quantitative values are presented as themean± standard devia-
tion (SD). Signiﬁcant differences were analyzed using Student's t-test. A
value of P b 0.05 was considered statistically signiﬁcant.ibit a decreased bone mass with an increased number of osteoclasts. (A) The expression
me PCR. The relative induction fold of miR-150 is presented. * P b 0.05; *** P b 0.001, vs.
= 5)weremeasured. (C) Transverse and longitudinal images of the proximal left femurs
V/TV, Tb.N, and Tb.Sp of femurs (n = 5) were analyzed using an μCT scanner and CTAn
AP staining. (F) The osteoclast surface per bone surface (Oc. S/BS)wasmeasured by imageJ.
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3.1. miR-150 is down-regulated during osteoclast differentiation and
mir-150 knockout mice exhibit decreased bone mass with an increased
number of osteoclasts
Several miRNAs have been reported to regulate osteoclast differen-
tiation (Xia et al., 2011; Kagiya & Nakamura, 2013). Here, we are the
ﬁrst to report that miR-150 expression is gradually down-regulated
during RANKL-mediated differentiation of normal BMMs into osteo-
clasts (Fig. 1A).
As reported previously (Xiao et al., 2007), miR-150 knockout mice
are viable, fertile, and morphologically normal. In the current study,
there were no differences in body weight between wild-type and
miR-150 knockout mice (Fig. 1B), but μCT analysis revealed that trabec-
ular bone mineral density (BMD), bone volume/tissue volume (BV/TV
or bone volume fraction), and the number of trabeculae (Tb.N) in
femurs were signiﬁcantly lower, and that trabecular separation (Tb.Sp)
greater, in miR-150 knockout mice, suggesting that miR-150-deﬁciency
is phenotypically osteoporotic (Fig. 1C and D). This suggestion was con-
ﬁrmed in H&E-stained and TRAP-stained histological sections showing
lower trabecular density and increased numbers of TRAP-stained osteo-
clasts in miR-150 knockout mice compared to the wild type (Fig. 1E
and F). In the subsequent experiments, we focused on the relevance of
miR-150 to the formation of osteoclasts.
3.2. Osteoclast differentiation of isolated BMMs is similar in miR-150
knockout and wild-type mice
In BMMs isolated from miR-150 knockout mice, the expression
levels of miR-150 were dramatically lower than those in wild-typeFig. 2.Osteoclast differentiation of BMMs isolated frommiR-150 knockoutmicewas similar to t
type or miR-150 knockout mice (KO) were evaluated by real-time PCR. The relative inductio
subsequently miR-150 expression levels were analyzed. *** P b 0.001, vs. the wild type. The ef
mRNA levels of genes related to osteoclast differentiation (E) and NFATc1 protein expression (
indicated RANKL and M-CSF (30 ng/ml), and stained with a TRAP solution, and then photograp
BMMs were cultured for the indicated days with M-CSF (30 ng/ml) and RANKL (10 ng/ml). The
tively (E, F).mice (Fig. 2A). However, when miR-150−/− BMMs differentiated into
osteoclasts, TRAP+-MNCs were normally formed as observed in wild
type (Fig. 2B). No difference was observed in the formation of TRAP+-
MNCs between wild-type and miR-150 knockout mice, nor was there
a difference in osteoclast differentiation as conﬁrmed by counting the
TRAP+-MNCs (Fig. 2C) and measuring TRAP activity (Fig. 2D). miR-
150 has been reported to regulate the cell fate of megakaryocyte-
erythroid progenitors (Lu et al., 2008) and its deﬁciency resulted in
the defective development of natural killer (NK) and invariant NK
T (iNKT) cells (Bezman et al., 2011; Zheng et al., 2012). miR-150 deﬁ-
ciency also reduced the capacity of Langerhans cells (LCs) for cross-
presentation, but it did not interrupt the development, maturation,
migration or phagocytic capacity of LCs (Mi et al., 2012). The ﬁndings
of our study suggest that miR-150 deﬁciency has no functional rele-
vance for the ability of precursors to differentiate into osteoclasts in
in vitro conditions.
3.3. miR-150 knockout mice have signiﬁcantly low serum levels of OPG, but
not RANKL, IFN-γ or TNF-α
As well as no difference in the thickness of cortical bone between
wild-type and miR-150 knockout mice (Supplementary Fig. 1), the
in vitro results showing that the retroviral over-expression of miR-150
did not affect either osteoclast or osteoblast differentiation (Supple-
mentary Fig. 2 and 3), along with the observation that miR-150 had
no functional relevance for the ability of precursors to differentiate
into osteoclasts in in vitro conditions, prompted us to further investigate
mir-150's effect on the serum levels of in vivo systematic factors such as
OPG, RANKL, IFN-γ and TNF-α. As shown in Fig. 3, miR-150 knockout
mice had signiﬁcantly lower serum levels of OPG, but not of RANKL,
IFN-γ or TNF-α.hat of thewild type. (A) The expression levels ofmiR-150 in BMMs isolated from thewild-
n fold of miR-150 is presented. BMMs were cultured with M-CSF (30 ng/ml) for 2 days,
fects of miR-150 deﬁciency on the formation of TRAP +−MNC (B, C), TRAP activity (D),
F) were evaluated. Brieﬂy, isolated BMMs were cultured for 4 days in the presence of the
hed under a light microscope (magniﬁcation ×100, B–D). For expression level evaluation,
mRNA and protein expression were analyzed by real-time PCR andWestern blot, respec-
Fig. 3.miR-150 knockoutmice had signiﬁcantly lower serum levels ofOPG, but not RANKL,
IFN-γ or TNF-α. Serum levels ofOPG, RANKL, TNF-α and IFN-γweremeasured using ELISA
assay kits as described in the Materials and methods section.
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established. OPG knockout mice display early-onset osteoporosis
leading to large numbers of osteoclasts and severe bone destruction
(Bucay et al., 1998). OPG production has been suggested to be attribut-
able to B cells as well as to osteoblasts and their precursors (Li et al.,
2007). Interestingly, HIV-induced B cell dysfunction leading to in-
creased RANKL and decreased OPG has recently been reported to corre-
late with loss of BMD (Titanji et al., 2014), and B-cell knockout mice
were shown to be deﬁcient in OPG and osteoporotic (Li et al., 2007).
However, considering the expansion of B1a cells in miR-150 knockout
mice (Xiao et al., 2007), the positive relationship between B cell func-
tion andOPG levelsmaynot explain the signiﬁcantly lower serum levels
of OPG in miR-150 mice.
Instead, we hypothesized that the reduction of OPG serum levels
in miR-150-deﬁcient mice might induce B cell expansion that subse-
quently increases serum levels of immunoglobulin (Ig) for activating
osteoclast differentiation. Higher numbers of pro- and mature splenic
B1 cells in OPG knockout mice have been reported (Yun et al., 2001).
This could be consistent with B1a cell expansion in miR-150 knockout
mice (Xiao et al., 2007). In addition, miR-150 deﬁciency resulted in
higher serum Ig levels due to B1a cell expansion in the spleen and peri-
toneal cavity;miR-150 knockoutmice exhibited a 9-fold increase in IgA,
a 4-fold increase in IgG2b, a 3-fold increase in IgG1, and a 2-fold increase
in IgM serum levels (Xiao et al., 2007). Considering that IgG auto-
antibody has been suggested to enhance osteoclast generation and
bone destruction via its binding to select activating cellular fragment
crystallizable (Fc)-γ receptors on immature osteoclasts (Seeling et al.,
2013), OPG reduction in miR-150 deﬁciency might induce osteoclast
differentiation via B cell expansion-mediated induction of IgG. In addi-
tion, the possibility that B1 cells differentiate into functional osteoclast-
like cells cannot be excluded when explaining osteoporotic bone in
miR-150 knockout mice (Pugliese et al., 2012). Furthermore, the acti-
vated B cells have been shown to enhance the osteoclastogenesis by
expressing many osteoclastogenic factors (Choi et al., 2001).T cells also induce B cell-mediated OPG production in vivo, and
T-cell-deﬁcient mice with diminished bone marrow OPG production
were also osteoporotic (Li et al., 2007). However, conventional T cell
development was normal under miR-150-deﬁcient conditions (Zheng
et al., 2012).
Activation of matured NK and iNKT cells was accompanied by the
production of IFN-γ to inhibit osteoclast formation (Takahashi et al.,
1986; Kamolmatyakul et al., 2001). In miR-150 knockout mice with
impaired NK cell maturation, defective IFN-γ production has been
observed (Bezman et al., 2011); compared to control, IFN-γ was pro-
duced by a signiﬁcantly smaller proportion of miR-150−/− NK cells in
response to in vitro stimulation. In addition, in vivo activated iNKT
cells in miR-150−/− mice exhibited signiﬁcantly higher production of
IFN-γ (Zheng et al., 2012), however the amounts of IFN-γ produced
by the controls and those by miR-150 knockout NK cells did not differ
under no-stimulus conditions (Bezman et al., 2011). Consistent with
this result, we observed no difference in IFN-γ serum levels between
control and miR-150 knockout mice, suggesting that IFN-γ could not
explain the osteoporotic bones of miR-150 knockout mice.
NK and iNKT cells have been shown to regulate osteoclast differenti-
ation by their activation or production of RANKL (Soderstrom et al.,
2010; Hu et al., 2011). It has been shown that NK cells are abundant in
the inﬂamed joints of patients with rheumatoid arthritis (Soderstrom
et al., 2010) and, conversely, that osteoporotic animals are characterized
by a reduced number of NK cells and osteoclasts (Popoff et al., 1991;
Roundy et al., 2003). In vivo activated iNKT cells promote the expansion
of osteoclast precursors and lead to accelerated maturation and activa-
tion of osteoclasts; in addition, IFN-γ and TNF-α have been suggested
to be negative and positive regulators of iNKT cell-induced osteoclast
development (Hu et al., 2011). The impaired maturation of both cells
has been reported in miR-150 deﬁciency (Bezman et al., 2011; Zheng
et al., 2012), but we observed no difference in the serum levels of IFN-
γ or TNF-α between the control and miR-150 knockout mice, suggest-
ing that the osteoporotic bones of miR-150 knockout mice cannot be
explained by the activity of NK and iNKT cells.
There are a lot of resources to produce OPG in the body. As well as
bone, mouse OPG mRNA has been reported to be expressed in several
tissues, including liver, lung, heart, kidney, stomach, intestines and
skin (Simonet et al., 1997), and furthermore, in marrow, it is produced
by a variety of cells, including stromal cells, B lymphocytes, and dendritic
cells. In this study, serum OPG level was decreased in KO mice. Overex-
pression of miR-150 in osteoblasts did not change OPG levels. Then,
which cells or tissues are responsible for the reduction of OPG in serum
of miR-150 KO mice? Unfortunately, we have no idea or evidence to
answer this question. This should be elucidated in a further study.4. Conclusion
miR-150 expressionwas down-regulated during osteoclast differen-
tiation, and miR-150 knockout mice exhibited decreased bone mass
with an increased number of osteoclasts. Osteoclast differentiation of
BMMs isolated from miR-150 knockout mice was similar to that of the
wild type; however, miR-150 knockout mice had signiﬁcantly lower
serum levels of OPG, but not RANKL, IFN-γ or TNF-α. In miR-150 deﬁ-
ciency, the reduction of serum OPG levels may induce B cell expansion
and subsequently increase serum levels of Igs that activate osteoclast
differentiation.Acknowledgments
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